metastatic/advanced - esophageal cancer (mEC) | |
mEC - 1st line (L1) | |
pembrolizumab plus SoC | KEYNOTE-590 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -